

From: [Nguyen, Janice](#)
To: [Todd Hockemeyer](#)
Cc: [Matthew Trusner](#)
Subject: NRC Request for Additional Information for Zevacor Pharma, Inc. (Mail Control Number 593112)
Date: Wednesday, April 12, 2017 2:28:00 PM

Licensee: Zevacor Pharma, Inc.
License No.: 45-25221-01MD
Docket No.: 030-32974
Control No.: 593112

PLEASE CONFIRM RECEIPT OF THIS REQUEST FOR ADDITIONAL INFORMATION BY RETURN EMAIL

Dear Mr. Hockemeyer:

This is in reference to your letter dated March 31, 2017, requesting to amend Nuclear Regulatory Commission License No. 45-25221-01MD and provide financial assurance for your license. In order to continue our review of your request for the Eckert and Ziegler GalliaPharm Ge-68/Ga-68 generator, we need the following additional information:

1. In your Payment Surety Bond dated March 23, 2017, we noted one error and two omissions. On page 1 of the document, the NRC license number should be corrected to NRC License #: 45-25221-01MD. Immediately following the corrected license number, you should include the license docket number and the amount for decommissioning activities guaranteed by this bond (i.e., \$225,000). On page 3 of the document, please confirm that Zevacor Pharma, Inc. does not have a seal. You may resubmit the corrected Payment Surety Bond in full, or you may amend the Payment Surety Bond dated March 23, 2017, by submitting an original letter signed by both original parties and include the requested changes/additions under amendment 1 of Payment Surety Bond dated March 23, 2017. If both parties are sending in separate signed copies, it is recommended that the signatures be notarized.
2. As indicated by Checklist 1, "Master Checklist for Decommissioning Financial Assurance," on page A-4 of NUREG-1757, Vol. 3, Rev. 1, and required by 10 CFR 30.35(b)(2), please submit a Certification of Financial Assurance. A Model Certification of Financial Assurance is shown under Table A.2.4. on pages A19-20.
3. As indicated by Checklist 5-A on page A-57 of NUREG-1757, Vol. 3, Rev. 1, please submit a Standby Trust Agreement and all supporting documentation (see Section A.12 and attach checklist 12-A). The model Standby Trust Agreement is shown under Table A.12.4, beginning on page A-131.
4. Please resubmit a copy of the legal binding agreement between Zevacor Pharma, Inc. and Eckert and Ziegler. The signature portion was not clear.

Please note that all financial assurance documents must be original copies with original signatures.

Additional guidance may be found in NUREG-1757, Volume 3, Revision 1, "Consolidated NMSS Decommissioning Guidance - Financial Assurance, Recordkeeping, and Timeliness," which may be found at: <https://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1757/v3/>.

We will continue our review upon receipt of the requested information. You may respond to my attention in writing by letter, referencing mail control number 593112. Please submit a reply within 30 days. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5006.

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Med, Ind, & Academic Uses**; then **Licensee Toolkits, see our toolkit index page**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

Thank you in advance for your help!

Sincerely,

Jan

Janice Nguyen
Senior Health Physicist
U.S. Nuclear Regulatory Commission
2100 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406
Office (610) 337-5006
FAX (610) 337-5269